Epstein-Barr virus reactivation and DNA damage response
Year: 2013
Type: dissertation
Abstract: The latent form of Epstein-Barr virus (EBV) is associated with many \nmalignancies, including nasopharyngeal carcinoma, which makes EBV itself an \nattractive target of therapy. The reactivation of EBV toward lytic gene \nexpression cascade will lead to expression of proteins involved in viral genome \nreplication and formation of new virions, which will induce a strong immune \nresponse. The kinases expressed exclusively during the lytic cycle will also \nsensitize the tumor cells to antiviral treatment. This concept has recently been \nincorporated into a combination therapy, referred to as cytolytic virus activation \ntherapy, in which a combination of gemcitabine (a chemoagent), valproic acid (a \nhistone deacetylase inhibitor) and subsequent addition of ganciclovir (an \nantiviral agent), has been used in clinical studies with promising results. The \nmolecular mechanisms by which these compounds co-operate, in order to \ntrigger DNA damage response with subsequent lytic induction and tumor \ncytotoxicity, is discussed in this review. These agents are shown to work in \nmultiple ways together. However, other EBV-associated malignancies might \nbenefit form different set of compounds and this needs to be investigated. \nFurther studies are required to analyze the effect of different combinations, in \norder to create potential stronger responses. These informations will be highly \nbeneficial to treat other EBV-associated malignancies by use of EBV as the \nmain target in a combination therapy.
Author: Farnaz Kouhestani
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G309912476, G7971379999
OpenAlex ID: W38502467
